Treatment Information

Back

Bladder Cancer treatment details. Biologic therapy.

Memorial Sloan-Kettering Cancer Center, New York, NY, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:New York, NY
Treatments:Biologic therapyHospital:Memorial Sloan-Kettering Cancer Center
Drugs:Journal:Link
Date:Feb 2010

Description:

Patients:
This phase II trial involved 45 previously-treated metastatic urothelial cancer patients with a median age of 64 years; 71% were male.

Treatment:
Patients were treated with the biologic therapy agent sunitinib, which is an inhibitor of proteins involved in supporting tumor blood supply.

Toxicities:
There was one reported treatment-related death due to heart attack. Grade 4 nausea, fatigue, lymphopenia, and thrombocytopenia were also reported.

Results:
The median overall survival was 7.1 months.

Support:
This study was partially supported by Pfizer Inc., the makers of sunitinib (Brand name: Sutent).

Correspondence: Dr. Dean Bajorin; email: [email protected]



Back